Scala Biodesign

Scala Biodesign announced it has raised $16 million in a Series A financing round, bringing its total funding to $21.5 million since its founding in 2022. The round was led by Grove Ventures, with participation from TLV Partners, Deep Insight, the Israel

TEL AVIV, Israel, March 31, 2026--Scala Biodesign Raises $16M Series A Financing to Accelerate Development of Protein-Based Products with ScalaOS

Scala's technology enables heat-stable, low-cost malaria vaccine protein to allow widespread use Why it matters Vaccines intended for widespread use in regions with unreliable electricity and limited cold-chain infrastructure must be produced in tens of m

Scala's technology stabilizes a dynamic target to accelerate drug discovery In collaboration with: Why it matters Structural information on protein targets is a cornerstone of drug development because it enables researchers to study how potential medicine

Scala's underlying technology enabled thermostable, long-lived enzyme variants that improve survival and brain function in neuronopathic Gaucher disease Why it matters Lysosomal storage disorders are often caused by unstable or short-lived enzymes that fa